Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 May-Jun;85(3):279-84.
doi: 10.1007/BF01907116.

Vasodilator actions of interleukin-1 in the canine coronary circulation

Affiliations

Vasodilator actions of interleukin-1 in the canine coronary circulation

D Kenny et al. Basic Res Cardiol. 1990 May-Jun.

Abstract

The effects of intracoronary ultrapure human Interleukin-1 on the regional distribution of coronary blood flow (radioactive microspheres), contractile function (subendocardial ultrasonic length gauges) and systemic hemodynamics were studied in open-chest, anesthetized dogs (n = 7). Bolus doses of Interleukin-1 (10, 20, and 30 u) administered directly into the left anterior descending coronary artery increased coronary blood flow from 43 to 71, 80 and 87 ml/min, respectively. The increase in blood flow produced by Interleukin-1 was distributed uniformly to the subendocardium, midmyocardium, and subepicardium of the left ventricular free wall without effect on regional function or systemic hemodynamics. Indomethacin (1 mg/kg i.v.) attenuated the increase in blood flow, especially to the subepicardium. Due to the selective diminution of the Interleukin-1-mediated increase in subepicardial blood flow by indomethacin, the subendocardial to subepicardial perfusion ratio was increased by Interleukin-1 in the presence of indomethacin. The present results demonstrate that Interleukin-1 has direct coronary vasodilator actions, a portion of which is mediated by a product of cyclooxygenase metabolism.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Circ Res. 1974 Dec;35(6):896-908 - PubMed
    1. Lab Invest. 1988 Apr;58(4):365-78 - PubMed
    1. Circ Res. 1988 Dec;63(6):1070-9 - PubMed
    1. Lymphokine Res. 1987 Fall;6(4):325-34 - PubMed
    1. J Pharmacol Exp Ther. 1984 Feb;228(2):510-22 - PubMed

Publication types